Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

• Status: Completed
• Trial end date: 2021-10-29
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LEO Pharma

Criteria

Key Inclusion criteria (Part 1: adults and adolescents; 12 years and above)

• Diagnosis of atopic dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria for AD

• Age 12 years and above at baseline

• AD involvement of 25-50% treatable body surface area (BSA) at screening and at baseline

• Moderate to severe AD (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of at least 3) at screening and at baseline

Key Inclusion criteria (Part 2: children; 2-11 years)

• Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD

• Age 2-11 years at baseline

• History of AD for at least 3 months (children aged 2-5 years), and at least 12 months (children aged 6-11 years)

• AD involvement of ≥35% treatable BSA at screening and at baseline

• Moderate to severe AD (vIGA-AD score of at least 3) at screening and at baseline

Key Exclusion criteria (Part 1 and 2: subjects aged 2 years and above)

• Active dermatologic conditions that may interfere with the diagnosis of AD

• Use of tanning beds or phototherapy within 4 weeks prior to baseline

• Systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline

• Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), topical phosphodiesterase-4, or oral antibiotics within 1 week prior to baseline

• Clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline

• Any disorder, which is not stable, and in the investigator's opinion could affect the safety of the subject, influence the results of the trial or impede the subject's ability to complete the trial